Data Integrity module
Feb 21 2018
LabWare has developed and launched a new data integrity module for its enterprise LIMS and ELN solution to help drug manufacturers conform to the FDA draft guidance on ‘Data Integrity and Compliance with CGMP’.
The new enhancement to LabWare LIMS & ELN ensures that companies are able to meet current and proposed regulatory guidance regarding the management of data in temporary memory. New and emerging data integrity standards put forth by the U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), and World Health Organization (WHO), which would require the capture of temporary data in electronic records.
The new features are in addition to LabWare current solution that supports a GxP-compliant audit trail based on a full history of analytical testing, including:
Forced Save during manual result entry, to mitigate manipulation of values in temporary memory.
Disabling manual entry when data is captured directly from instrumentation
Forced reviews of Audit Trail entries when exceptions occur, such as result modification
Checksum generation and checking against data records, to detect manipulation.
Date time of data entry
Electronic Signature and mandatory reason for change
In This Edition Articles - The challenges of Biosample access and what needs to change - Innovative UK exports must gather income - not dust Spotlight Life Sciences - How a Pipettin...
View all digital editions
Sep 21 2021 Lagos, Nigeria
Sep 27 2021 Virtual event
Sep 27 2021 Beijing, China
Sep 28 2021 Glasgow, Scotland
Sep 29 2021 Online event